Navigation Links
Pittsburgh Life Sciences Greenhouse Closes $315,000 In Half-Year Investments
Date:7/15/2013

PITTSBURGH, July 15, 2013 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the region's only pure life sciences investment firm, and managing member of the PLSG Accelerator Fund, announced today that it closed seven investments totaling more than $315,000 in the first half of 2013.  The investments demonstrate continued commitment to the Western Pennsylvania region and the life sciences industry.

Three participating companies, Wellbridge Health, PHRQL Inc. and NewCare Solutions, are in the growing Healthcare Information Technology (HIT) segment and are first-time investments for PLSG. Follow-on investment companies that PLSG has remained committed and active with include Alung Technologies Inc., ATRP Solutions, MS2 Array LLC. and Quantum Ops.

"These modest, but important investments were very timely for the companies and were carefully chosen as the PLSG keeps its focus on organizations that offer the best chance for success and investment returns," said John Manzetti, PLSG President and CEO. "The demand for capital from both the PLSG and PLSG Accelerator Fund continues to grow and is now more than six times our capital available to invest. We will return to our more robust levels of investing when our current portfolio companies begin to exit."

For more information about the PLSG, visit www.plsg.com or call 412-201-7370.

About Pittsburgh Life Sciences Greenhouse (PLSG) (www.plsg.com)
The PLSG invests in and supports the growth of biosciences companies in western Pennsylvania. PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region. Since PLSG began operation in 2002, it has assisted more than 400 life sciences companies and has helped create or retain nearly 6,000 jobs in western Pennsylvania. Thirty-four companies have been provided with office or laboratory space and 13 have been relocated to Pittsburgh from outside of the region. In addition, the PLSG has invested nearly $19 million in 76 companies which has leveraged nearly $900 million in additional capital to the region.

About PLSG Accelerator Fund (www.acceleratorfund.com)
The PLSG Accelerator Fund I, which had its final closing in December, 2012 at $8.1 million, currently is fully invested in eight portfolio companies.  The Accelerator Fund provides regional life sciences companies with venture capital financing, which is the next step beyond capital provided by economic development organizations; friends and family; and angel investors.  The Accelerator Fund is building a portfolio of early-stage life sciences investments, primarily located in western Pennsylvania and spread across several life sciences investments, primarily located in western Pennsylvania and spread across several life sciences sectors including medical devices, diagnostics, therapeutics, healthcare information technology and biotechnology tools. 


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Proposals Now Being Accepted for the 2014 Pittsburgh Conference Memorial National College Grants (PCMNCG)
2. Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
3. Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device
4. Pittsburghs Positive Investment Growth Bucks National Trends According to Ernst & Young and Innovation Works Report
5. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
6. The Pittsburgh Life Sciences Greenhouse Congratulates Dr. Paul L. Kornblith, M.D., on Being Named the 2013 recipient of the Schoemaker Award
7. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
8. PointCross Life Sciences Opens New Office in Silver Spring, Maryland for Data Standardization of Nonclinical Studies
9. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
10. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
11. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... NC (PRWEB) , ... February 23, 2017 , ... ... to announce a new partnership with Compass Research . GGI's mission is to ... a vaccine to a child in need in honor of each clinical trial volunteer. ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members of ... Fellows of the Society this year, the Fellows Committee has announced. The honor ... optics, photonics, and imaging as well as their service to the Society and ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):